Physician profile
Cesar E Coello
NPI 1003997560
$4,615.52
in general payments reported to CMS, 2019-2025
26 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $186 · 2021: $126 · 2022: $1,641 · 2023: $101 · 2024: $649 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882 · Travel and Lodging: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,881.85 |
| Travel and Lodging | $351.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,044.19 | 2022-2025 | Micra |
| Amgen INC. | $467.42 | 2019-2025 | Repatha |
| Abiomed | $318.89 | 2024-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $294.29 | 2019-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.90 | 2022-2025 | Jardiance |
| Boston Scientific Corporation | $253.23 | 2019-2025 | Watchman Access System, Emerge Push |
| Novartis Pharmaceuticals Corporation | $167.40 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $107.88 | 2019-2024 | Xarelto |
| Livanova USA, INC. | $101.91 | 2019 | |
| Biosense Webster, INC. | $91.89 | 2025 | Carto 3 |
| Abbott Laboratories | $83.21 | 2021 | |
| Edwards Lifesciences Corporation | $50.86 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $48.80 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.66 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $36.10 | 2024-2025 | Amvuttra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $32.40 | 2022-2023 | Kengreal |
| Bayer Healthcare Pharmaceuticals INC. | $23.90 | 2025 | |
| Angiodynamics, INC. | $22.17 | 2021 | |
| Merck Sharp & Dohme LLC | $21.11 | 2023 | Verquvo |
| Lantheus Medical Imaging, INC. | $20.14 | 2021 | |
| Inari Medical, INC. | $17.75 | 2020 | |
| Cardiovascular Systems INC. | $17.63 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $17.45 | 2024 | Brilinta |
| Gilead Sciences, INC. | $14.70 | 2019 | |
| Cvrx, INC. | $14.51 | 2025 | Barostim Neo System |
| Teleflex LLC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Coello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.